Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes.

Fu-Shun YenJames Cheng-Chung WeiMei-Chen LinChih-Cheng Hsu Chii-Min Hwa

Published in: BMC endocrine disorders (2021)

AGI use was associated with higher risks of all-cause mortality and non-cardiovascular death in insulin-treated patients with T2DM. Therefore, adding AGIs in insulin-treated patients may not be appropriate.

Keyphrases

type diabetes
newly diagnosed
glycemic control
end stage renal disease
chronic kidney disease
prognostic factors
peritoneal dialysis
adipose tissue
human health
climate change